A study in myelodysplastic (MDS) patients showed that expression of RPL23 is much higher in high-risk MDS patients than low-risk MDS patients and this higher expression was associated with resistance to apoptosis and increased c-Myc expression [199]. This evidence concerns the gene RPL23 and myelodysplastic syndrome.